Malaria vaccines
Tóm tắt
Significant progress has been made in the development of the malaria vaccine during the last 20 years. Ninety percent of the 300–500 million clinical cases of malaria per year worldwide occur in Africa. Thus, research must be directed toward the 1 million African children under 5 years of age who die every year of malaria. An asexual blood-stage vaccine, capable of reducing severe and complicated malaria and malaria-related mortality, is therefore an important public health tool in these countries. Although knowledge of the parasite's biology is incomplete, research has allowed insight into some of the mechanisms that the parasite uses to evade host immunity. This is the basis for adopting an “antigenic cocktail” approach toward obtaining a synthetic or recombinant subunit vaccine such as the synthetic Colombian Malaria vaccine SPf 66. During the development of Spf66, field trials under both low and high malaria endemicity areas in Latin America and Africa have been carried out. The results from these studies showed a protective efficacy ranging between 38.8 and 60.2% againstPlasmodium falciparum malaria. Given the characteristics of the normal immune response to malaria (relatively short-lived and not completely effective), it is understandable that the main goal is to try to increase the host's natural immunity. The best candidates for designing a malaria vaccine are the proteins required for parasite survival, those with low mutation rates and conserved epitopes. Because these proteins play an important role in multiple or alternative steps during the invasion process, they should be the targets against which a protective immune response should be elicited. The interaction between the malaria parasite and its host is complex. It is therefore crucial to define new ways of improving the immune response—such as directly modifying the chemical structure of epitopes or using new adjuvants or DNA immunization techniques—to produce novel vaccines against this disease.
Tài liệu tham khảo
Amador R, Moreno A, Valero MV, Murillo LA, Mora AL, Rojas M, Rocha CL, Salcedo M, Guzmán F, Espejo F, Nuñez F, Patarroyo ME: The first field trials of the chemically synthetized malaria vaccine SPf66: safety, immunogenicity and protectivity. Vaccine 10:179–184, 1992
Lopez MC, Silva Y, Thomas MC, Garcia A, Faus MJ, Alonso PL, Martinez F, Del Real G, Alonso C: Characterization of SPf(66)n: A chimeric molecule used as a malaria vaccine. Vaccine 12:585–591, 1994
Moreno A, Patarroyo ME: Development of an asexual blood stage malaria vaccine. Blood 74:537–546, 1989
Herrington DA, Clyde DF, Davis JR, Baqar S, Murphy JR, Cortese JF, Bank RS, Nardin E, DiJohn D, Nussenzweig RS,et al.: Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. Bull WHO 68 (Suppl):33–37, 1990
Kaslow DC, Isaacs SN, Quakyi IA, Gwadz RW, Moss B, Keister DB: Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science 252:1310–1313, 1991
Deloron P, Campbell GH, Brandling-Bennett D, Roberts JM, Schwartz IK, Odera JS, Lal AA, Osanga CO, de la Cruz V, McCutchan TM: Antibodies to Plasmodium falciparum ring-infected erythrocyte surface antigen and P. falciparum and P. malariae circumsporozoite proteins: Seasonal prevalence in Kenyan villages. Am J Trop Med Hygiene 41:395–399, 1989
Day KP, Marsh K: Naturally acquired immunity toPlasmodium falciparum. Immun Today 12:68–71, 1991
Marsh K, Howard RJ: Antigens induced on erythrocytes by P. falciparum: Expression of diverse and conserved determinants. Science 231:150–153, 1986
Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Sinigaglia F, Nardin E: CD4+ T cell clones obtained fromPlasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the Circumsporozoite protein. J Immunol 151:489–499, 1993
Hadley Terence J, Miller LH, Haynes J. David: Recognition of red cells by malaria parasites: the role of erythrocyte-binding proteins. Transfus Med Rev 5:108–122, 1995
Molano A, Segura C, Guzman F, Lozada D, Patarroyo ME: In human malaria protective antibodies are directed mainly against the Lys-Glu ion pair within the Lys-Glu-Lys motif of the synthetic vaccine SPf66. Parasite Immunol 14:111–124, 1992
Murphy VF, Rowan WC, Page MJ, Holder AA: Expression of hybrid malaria antigens in insect cells and their engineering for correct folding and secretion. Parasitology 100:177–183, 1994
Satterthwait AC, Arrhenius T, Hagopian RA, Zavala F, Nussenzweig V, Lerner RA: The conformational restriction of synthetic peptides, including a malaria peptide, for use as immunogens. Philo Trans Roy Soc London Ser B Biol Sci 323(3):72, 1989
Satterthwait AC, Chiang LC, Arrhenius T, Cabezas E, Zavala F, Dyson HJ, Wright PE, Lerner RA: The conformational restriction of synthetic vaccines for malaria. Bull WHO 68 (Suppl):17–25, 1990
Merrifield R: Solid-phase peptide synthesis. I. The synthesis of of a tetrapeptide. J Am Chem Soc 85:2149–2154, 1963
Houghten R: General method for the rapid solid phase synthesis of large numbers of peptides: Specificity of antigen antibody interaction at the level of individual aminoacids. Proc Natl Acad Sci USA 82:5131–5135, 1995
Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzmán F, Romero P, Tascón R, Franco A, Murillo LA, Pontón G, Trujillo G: A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332:158–161, 1988
Alonso PL, Teuscher T, Tanner M: SPf66: Research for development or development of research? Vaccine 12:99–101, 1994
WHO Malaria Action Programme: Guidelines for the evaluation ofPlasmodium falciparum asexual blood-stage vaccines in populations exposed to natural infection, 1989, pp 1–34
Ballou WR: Clinical trials of plasmodium falciparum erythrocytic stage vaccines. Am J Trop Med Hyg 50:59–65, 1995
Alonso PL, Tanner M, Smith T, Hayes RJ, Schellenberg JRM, Lopez MC, Bastos de Azevedo I, Menendez C, Lyimo E, Weiss N, Kilama WL, Teuscher T: A trial of the synthetic malaria vaccine SPf66 in Tanzania: Rationale and design. Vaccine 12:181–186, 1994
Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Mora AL, Rocha CL, Alvarado F, Falla JC, Orozco MA, Coronell CG, Ortega NM, Molano A, Velásquez JF, Valero MV, Franco LC, Guzmán F, Salazar LM, Espejo F, Mora E, Farfán R, Zapata N, Rosas JE, Calvo JC, Castro J, Quiñonez T, Nuñez F, Patarroyo ME: Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J Infect Dis 166:139–144, 1992
Patarroyo G, Franco LC, Amador R, Murillo LA, Rocha CL, Rojas M, Patarroyo ME: Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1–14 years. Vaccine 10:175–178, 1992
Rocha CL, Murillo LA, Mora AL, Rojas M, Franco LC, Cote J, Valero MV, Moreno A, Amador R, Nuñez F, Coronell CG, Patarroyo ME: Determination of the immunization schedule for field trials with the sybthetic malaria vaccine SPf66. Parasite Immunol 14:95–109, 1992
Valero MV, Amador R, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M, Aponte JJ, Sarmiento LE, Lozada DM, Coronell CG, Ortega NM, Rosas JE, Alonso PL, Patarroyo ME: Vaccination with SPf66, a chemically synthesised vaccine, againstPlasmodium falciparum malaria in Colombia. Lancet 341:705–710, 1993
Noya O, Gabaldon I, de Noya B, Borges R, Zerpa N, Urbáez JD, Madonna A, Garrido E, Jimenez MA, Borges RE, Garcia P, Reyes I, Prieto W, Colmenares C, Pabón R, Barraez T, de Caceres LG, Godoy N, Sifontes R: A population-based clinical trial with the SPf66 syntheticPlasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 170:396–402, 1993
Sempértegui F, Estrella B, Moscoso J, Piedrahita CL, Hernández D, Gaybor J, Naranjo P, Mancero O, Arias S, Bernal R, Córdova ME, Suarez J, Zicker F: Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine againstPlasmodium falciparum infection in randqmized double-blind placebocontrolled field trial in an endemic area of Ecuador. Vaccine 12:337–342, 1994
Valero MV, Amador R, Aponte JJ, Narvaez A, Galindo C, Silva Y, Rosas J, Guzman F, Patarroyo ME: “Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia.” 1996 Vaccine (in press)
Bothamley GH, Beck JS, Potts RC, Grange JM, Kardjito T, Ivanyi J: Specificity of antibodies and tuberculin response after occupational exposure to tuberculosis. J Infect Dis 166:182–186, 1992
Teuscher T, Schellenberg JRM, Bastos de Azevedo I, Hurt N, Smith T, Hayes RJ, Masanja H, Silva Y, Machin D, Kitua A, Kilama WL, Tanner M, Alonso PL: SPf66, a chemically synthesized subunit malaria vaccine, is safe and immnunogenic in Tanzanians exposed to intense malaria transmission. Vaccine 12:328–336, 1994
Trape J, Rogier C: Efficacy of SPf66 vaccine againstPlasmodium falciparum malaria in children. Lancet 345:134–135, 1995 (abstr)
D'lessandro U, Leach A, Drakely ChJ, Bennett S, Olaleye BO, Fegan GW, Jawara M, Lanrerock P, George MO, Targett GAT, Greenwood BM: Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 146:462–467, 1995 (Abstr)
Ada G: Strategies for exploiting the immune system in the design of vaccines. Mol Immunol 28:225–230, 1995 (abstr)
Long CA, Daly TM, Kima P, Srivastava I: Immunity to erythrocytic stages of malarial parasites. Am J Trop Med Hyg 50:27–32, 1994
Mendis KN, Carter R: Clinical disease and pathogenesis in malaria. Parasitol Today 11:PTI 2-PTI 16, 1995 (abstr)
Salcedo M, Barreto L, Rojas M, Moya R, Cote J, Patarroyo ME: Studies on the humoral immune response to a synthetic vaccine againstPlasmodium falciparum malaria. Clin Exp Immunol 84:122–128, 1991
Murillo LA, Rocha CL, Mora AL, Kalil J, Goldemberg AK, Patarroyo ME: Molecular analysis of each HLA DR4 B-1 gene in malaria vaccines. Typing and subtyping by PCR technique and oligonucleotides. Parasite Immunol 13:201–210, 1992
Murillo LA, Tenjo F, Clavijo O, Orozco M, Sampaio S, Kalil J, Patarroyo ME: A specific T cell-receptor genotype preference in the immune response to a syntheticPlasmodium falciparum malaria vaccine. Parasite Immunol 14:87–94, 1992
Nardin EH, Nussenzweig RS: T cell responses to pre-erythrocytic stages of malaria: Role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 11:687–727, 1993
Hollingdale MR, Aikawa M, Atkinson CT, Ballou WR, Chen GX, Li J, Meis JF, Sina B, Wright C, Zhu JD: Non-CS pre-erythrocytic protective antigens. Immunol Lett 25:71–76, 1990
Lalvani A, Aidoo M, Allsopp CE, Plebanski M, Whittle HC, Hill AV: An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum. Res Immunol 145:461–468, 1994
Good MF: Antigenic diversity and MHC genetics in sporozoite immunity. Immunol Lett 41:95–98, 1994
Romero P: Malaria vaccines. Curr Biol 4:432–441, 1992 (abstr)
Radack KL, Rouan G, Hedges J: The likelihood ratio. An improved measure for reporting and evaluating diagnostic test results. Arch Pathol Lab Med 110:689–693, 1986
Huang W, Nardelli B, Tarn J: Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine. Mol Immunol 31:1191–1199, 1995 (abstr)
Hui GSN: Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines. Am J Trop Med Hyg 50:41–51, 1994
Kensil CR, Newman MJ, Coughlin RT, Soltysik S, Bedore D, Recchia J, Wu J, Marciani DJ: The use of Stimulon adjuvant to boost vaccine response. Vacc Res 2:273–281, 1995 (abstr)
WHO Division of Control of Tropical Diseases, World Bank: The potential impact of research and development on malaria control activities, 1993, pp 1–20 (abstr)
WHO: Tropical disease research: Progress 1975–94: Highlights 1993–94: Twelfth programme report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). 1:57–76, 1995 (abstr)
WHO Division of Control of Tropical Diseases: Outline for WHO's plan of work for malaria control 1993–2000, 1992, pp 1–21 (abstr)
Nájera JA, Liese BH, Hammer J: Malaria. New patterns and perspectives. 1–32, 1992 (World Bank)